Who are PVC (twice weekly)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Multaq, Tikosyn, Corvert, Tambocor, Cordarone, Mexitil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pvc-twice-weekly.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PVC (twice weekly) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PVC (twice weekly) (PVC (twice weekly)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

phase 3 Antiarrhythmic AV node, bundle of His Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

PVC (twice weekly) (PVC (twice weekly)) — Wyeth is now a wholly owned subsidiary of Pfizer. PVC works by blocking the action of certain electrical signals in the heart, helping to regulate its rhythm.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PVC (twice weekly) TARGET	PVC (twice weekly)	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Antiarrhythmic	AV node, bundle of His
Multaq	DRONEDARONE	Sanofi	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily KQT member 2	2009-01-01
Tikosyn	DOFETILIDE	Pfizer	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily H member 2	1999-01-01
Corvert	IBUTILIDE	Pfizer	marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1995-01-01
Tambocor	FLECAINIDE		marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1985-01-01
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
Mexitil	MEXILETINE	Boehringer Ingelheim	marketed	Antiarrhythmic	5-hydroxytryptamine receptor 2B	1985-01-01

Recent regulatory actions (last 90 days)

2026-03-23 — Mexitil · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic class)

Pfizer · 3 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Boehringer Ingelheim · 1 drug in this class
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
Eli Lilly · 1 drug in this class
MTI Medical Private Limited, Pakistan · 1 drug in this class
Technical University of Munich · 1 drug in this class
· 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PVC (twice weekly) — Competitive Intelligence Brief. https://druglandscape.com/ci/pvc-twice-weekly. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing